biopsies may be considered in 3 years. Patients with advancedstages of atrophic gastritis should be followed up with ahigh quality endoscopy every 3 years. In patients with dysplasia, in the absence of an endoscopically defined lesion,immediate high quality endoscopic reassessment with CEis recommended. Patients with an endoscopically visible lesion harboring low or high grade dysplasia or carcinomashould undergo staging and treatment. H. pylori eradicationheals nonatrophic chronic gastritis, may lead to regressionof atrophic gastritis, and reduces the risk of gastric cancerin patients with these conditions, and it is recommended.H. pylori eradication is also recommended for patients withneoplasia after endoscopic therapy. In intermediate to highrisk regions, identification and surveillance of patients withprecancerous gastric conditions is cost-effective.